logo

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 11806374 B1

PDFFull Text
Date of Patent:
Nov. 07, 2023

Filed:

Jul. 03, 2018

Isolated recombinant oncolytic adenoviruses, pharmaceutical compositions, and uses thereof for drugs for treatment of tumors and/or cancers

Applicant:

Hangzhou Converd Co., Ltd., Hangzhou, CN;

Inventors:

Jipo Sheng, Hangzhou, CN;

Jin Fu, Hangzhou, CN;

Ronghua Zhao, Hangzhou, CN;

Yun Qin, Hangzhou, CN;

Lin Chen, Hangzhou, CN;

Sanmao Kang, Hangzhou, CN;

Fang Hu, Hangzhou, CN;

Assignee:

HANGZHOU CONVERD CO., LTD., Hangzhou, CN;

Attorney:

Renner, Otto, Boisselle & Sklar, LLP

Primary Examiner:

Shin Lin Chen

Int. Cl.
CPC ...
A61K 39/23 (2006.01); C12N 15/79 (2006.01); C07H 21/04 (2006.01); A61K 35/761 (2015.01); A61P 35/00 (2006.01); C12N 7/00 (2006.01); C12N 15/113 (2010.01); C12N 15/63 (2006.01); A61K 48/00 (2006.01); C12N 15/64 (2006.01);
U.S. Cl.
CPC ...
A61K 35/761 (2013.01); A61K 48/005 (2013.01); A61P 35/00 (2018.01); C12N 7/00 (2013.01); C12N 15/113 (2013.01); C12N 15/1135 (2013.01); C12N 15/63 (2013.01); C12N 15/64 (2013.01); C12N 2310/531 (2013.01); C12N 2710/10332 (2013.01); C12N 2710/10343 (2013.01);
Abstract

The present disclosure provides an isolated recombinant oncolytic adenovirus, a pharmaceutical composition, and uses thereof for drugs for treatment of tumors and/or cancers. The recombinant oncolytic adenovirus is a selectively replicating oncolytic adenovirus, and the genome of the recombinant oncolytic adenovirus is integrated with a coding sequence of exogenous shRNA capable of inhibiting PDL1 expression in tumor cells. The replication capability of the virus in normal primary cells is much lower than the replication capability of the virus in tumor cells. Moreover, the expressed shPDL1 can significantly reduce the level of PDL1 protein highly expressed in tumor cells. Thus, the oncolytic killing effect of the oncolytic virus and the anti-tumor immunostimulatory effect of immune cells produce a synergistic effect.

Find Patent Forward Citations

Sheng, Jipo. (2023). Isolated recombinant oncolytic adenoviruses, pharmaceutical compositions, and uses thereof for drugs for treatment of tumors and/or cancers (U.S. Patent No. 11806374). U.S. Patent and Trademark Office. https://idiyas.com/patent/badge/11806374

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Loading…